| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.26 | 3e-08 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.18 | 0.0001 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.22 | 0.0004 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.19 | 0.0008 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.002 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |